About this program

IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody (IgG1), designed to selectively destroy cutaneous T-cell lymphomas (CTCL) cancer cells. CTCL is a group of rare cutaneous lymphomas of T lymphocytes with poor prognosis and few therapeutic options at advanced stages.

KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all subtypes of the orphan indication of CTCL and expressed by up to 95% of certain agressive CTCL subtypes, in particular, Sésary syndrome and transformed mycosis fungoides. 

IPH4102 selectively binds KIR3DL2 and has demonstrated a high level of efficacy in various preclinical models. It has been granted orphan drug designation in the European Union for the treatment of CTCL.

IPH4102 is currently in Phase I trial for the treatment of CTCL. Biomarker tools are developed in parallel to allow the monitoring of KIR3DL2 expression in patients.

    Mechanism of action of anti-KIR3DL2

    IPH4102 selectively binds KIR3DL2 and aims at depleting cancer cells.

    IPH4102 high level of efficacy has been demonstrated in various preclinical models:

    • Potent antitumor properties of IPH4102 were shown against human CTCL cells in vitro and in vivo in a mouse model of KIR3DL2+ tumors, in which IPH4102 reduced tumor growth and improved survival.
    • The efficacy of IPH4102 was further evaluated in laboratory “ex vivo” assays using the patients’ own natural killer (NK) cells against their primary tumor samples in the presence of IPH4102. These studies were performed in patients with Sézary Syndrome; Sézary Syndrome is the leukemic form of CTCL and is known to have a very poor prognosis. In these experiments, IPH4102 selectively and efficiently induced killing of the patients’ CTCL cells. These results were published in Cancer Research in 2014.

    IPH4102 is currently in a Phase I trial for the treatment of relapsed/refractory CTCL.

    The Phase I trial is an open label and multicenter study. It is performed in Europe (France, Netherlands, United Kingdom) and in the US. Participating institutions include several hospitals with internationally recognized expertise: the Saint-Louis Hospital (Paris, France), the MD Anderson Cancer Center (Houston, Texas), the Stanford University Medical Center (Stanford, CA), the Ohio State University (Columbus, OH), the Leiden University Medical Center (Netherlands), and the Guy’s and St Thomas’ Hospital (United Kingdom). 45 to 60 patients with KIR3DL2-positive CTCL having received at least two prior lines of systemic therapy are expected to be enrolled in two sequential study parts:

    • A dose-escalation part including 25 to 40 CTCL patients in 10 dose levels. Its objective is to identify the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose (RP2D); the dose escalation follows an accelerated 3+3 design;
    • A cohort expansion part with 2 cohorts of 10 patients each in 2 CTCL subtypes (transformed mycosis fungoides and Sézary syndrome) receiving IPH4102 at the RP2D until progression. The cohort design (CTCL subtype, number of patients) could be revisited based on the findings in the dose escalation part of the study.

    The primary objective of this trial is to evaluate the safety and tolerability of repeated administrations of single agent IPH4102 in this patient population. The secondary objectives include assessment of the drug’s antitumor activity. A large set of exploratory analyses aims at identifying biomarkers of clinical activity. Clinical endpoints include overall objective response rate, response duration and progression-free survival.

    Encouraging preliminary safety and clinical activity results from the dose-escalation part of the Phase I study in patients with relapsed/refractory CTCL have been presented in a poster at the 3WCCL and ASH annual meeting 2016.

    Opinion Leader event chaired by Pr. Youn H. Kim, MD, Professor of Dermatology, Director of the Multidisciplinary Cutaneous Lymphoma Program and Medical Director of the Photopheresis Service at the Stanford Medical Center (New-York, October 2015)

    Key Opinion Leader event chaired by Pr Martine Bagot, Head  of  the Dermatology  Department  at  the  Saint-Louis  Hospital  in Paris  and  co-discoverer  of  the  target  KIR3DL2 (Paris, December 2015) - in French

    WARNING: some images may offend the sensibilities